Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, Oh DY, Chie EK, Lee JM, Heo JS, Park JO, Lim DH, Kim SH, Park SJ, Lee WJ, Koh YH, Park JS, Yoon DS, Lee IJ, Choi SH.
Jang JY, et al. Among authors: lee h, lee kh, lee ij, lee jm, lee wj.
Ann Surg. 2018 Aug;268(2):215-222. doi: 10.1097/SLA.0000000000002705.
Ann Surg. 2018.
PMID: 29462005
Clinical Trial.